Effect of TRPV2 cation channels on the proliferation, migration and invasion of 5637 bladder cancer cells

Liu,Quanliang; Wang,Xinghuan

doi:10.3892/etm.2013.1301

Effect of TRPV2 cation channels on the proliferation, migration and invasion of 5637 bladder cancer cells

Authors:
- Quanliang Liu
- Xinghuan Wang
View Affiliations

Affiliations: Department of Urology Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: September 13, 2013 https://doi.org/10.3892/etm.2013.1301
Pages: 1277-1282

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Transient receptor potential vanilloid 2 (TRPV2), a nonselective cation channel, has become an attractive target gene for tumor studies due to its wide range of physiological and pathological functions. However, its specific role in bladder cancer development and progression remains unclear. The aim of the present study was to investigate the effects of TRPV2 on the proliferation, migration and invasion of 5637 bladder cancer cells in vitro. Rat TRPV2 cDNA was transfected into 5637 bladder cancer cells and changes in the behavior of the cells were detected. It was observed that TRPV2 enhanced bladder cancer cell migration and invasion; however, it did not affect cell proliferation in vitro. TRPV2 activity, which may be mediated by direct matrix metalloproteinase 2 (MMP2) regulation, is important in bladder tumor development and progression. The results of this study suggest that TRPV2 channels are a potential therapeutic target for bladder carcinoma.

View Figures

View References

1.	Chen WQ, Zeng HM, Zheng RS, Zhang SW and He J: Cancer incidence and mortality in china, 2007. Chin J Cancer Res. 24:1–8. 2012. View Article : Google Scholar
2.	Elsobky E, El-Baz M, Gomha M, Abol-Enein H and Shaaban AA: Prognostic value of angiogenesis in schistosoma-associated squamous cell carcinoma of the urinary bladder. Urology. 60:69–73. 2002. View Article : Google Scholar : PubMed/NCBI
3.	Prevarskaya N, Flourakis M, Bidaux G, Thebault S and Skryma R: Differential role of TRP channels in prostate cancer. Biochem Soc Trans. 35:133–135. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Caterina MJ, Rosen TA, Tominaga M, Brake AJ and Julius D: A capsaicin-receptor homologue with a high threshold for noxious heat. Nature. 398:436–441. 1999. View Article : Google Scholar : PubMed/NCBI
5.	Neeper MP, Liu Y, Hutchinson TL, Wang Y, Flores CM and Qin N: Activation properties of heterologously expressed mammalian TRPV2: evidence for species dependence. J Biol Chem. 282:15894–15902. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Kanzaki M, Zhang YQ, Mashima H, Li L, Shibata H and Kojima I: Translocation of a calcium-permeable cation channel induced by insulin-like growth factor-I. Nat Cell Biol. 1:165–170. 1999. View Article : Google Scholar : PubMed/NCBI
7.	Everaerts W, Gevaert T, Nilius B and De Ridder D: On the origin of bladder sensing: Tr(i)ps in urology. Neurourol Urodyn. 27:264–273. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Nilius B, Owsianik G, Voets T and Peters JA: Transient receptor potential cation channels in disease. Physiol Rev. 87:165–217. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Prevarskaya N, Zhang L and Barritt G: TRP channels in cancer. Biochim Biophys Acta. 1772:937–946. 2007. View Article : Google Scholar
10.	Lehen’kyi V and Prevarskaya N: Study of TRP channels in cancer cells. TRP Channels. Zhu MX: CRC Press; Boca Raton, FL: Chapter 17. 2011, PubMed/NCBI
11.	Santoni G and Farfariello V: TRP channels and cancer: new targets for diagnosis and chemotherapy. Endocr Metab Immune Disord Drug Targets. 11:54–67. 2011. View Article : Google Scholar : PubMed/NCBI
12.	Gkika D and Prevarskaya N: TRP channels in prostate cancer: the good, the bad and the ugly? Asian J Androl. 13:673–676. 2011. View Article : Google Scholar : PubMed/NCBI
13.	Ziglioli F, Frattini A, Maestroni U, Dinale F, Ciufifeda M and Cortellini P: Vanilloid-mediated apoptosis in prostate cancer cells through a TRPV-1 dependent and a TRPV-1-independent mechanism. Acta Biomed. 80:13–20. 2009.PubMed/NCBI
14.	Caprodossi S, Lucciarini R, Amantini C, et al: Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage. Eur Urol. 54:612–620. 2008. View Article : Google Scholar
15.	Yamada T, Ueda T, Shibata Y, et al: TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer. Urology. 76:509.e1–509.e7. 2010. View Article : Google Scholar
16.	Yang ZH, Wang XH, Wang HP and Hu LQ: Effects of TRPM8 on the proliferation and motility of prostate cancer PC-3 cells. Asian J Androl. 11:157–165. 2009. View Article : Google Scholar : PubMed/NCBI
17.	Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD and Julius D: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 389:816–824. 1997. View Article : Google Scholar
18.	Liedtke W, Choe Y, Martì-Renom MA, et al: Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell. 103:525–535. 2000. View Article : Google Scholar : PubMed/NCBI
19.	Ridley AJ, Schwartz MA, Burridge K, et al: Cell migration: integrating signals from front to back. Science. 302:1704–1709. 2003. View Article : Google Scholar : PubMed/NCBI
20.	Monet M, Gkika D, Lehen’kyi V, et al: Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta. 1793:528–539. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Chuang CK, Pang ST, Chuang TJ and Liao SK: Profiling of matrix metalloproteinases and tissue inhibitors of metalloproteinases proteins in bladder urothelial carcinoma. Oncol Lett. 1:691–695. 2010. View Article : Google Scholar : PubMed/NCBI
22.	Monet M, Lehen’kyi V, Gackiere F, et al: Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. Cancer Res. 70:1225–1235. 2010. View Article : Google Scholar : PubMed/NCBI
23.	Kader AK, Liu J, Shao L, et al: Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res. 13:2614–2620. 2007. View Article : Google Scholar : PubMed/NCBI
24.	Nakajima M, Welch DR, Wynn DM, Tsuruo T and Nicolson GL: Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res. 53:5802–5807. 1993.PubMed/NCBI
25.	Stearns ME and Wang M: Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. Cancer Res. 53:878–883. 1993.PubMed/NCBI
26.	Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M and Kagawa S: Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer. 82:1359–1366. 1998. View Article : Google Scholar : PubMed/NCBI
27.	Coussens LM, Fingleton B and Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI
28.	Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG and Quaranta V: Induction of cell migration by matrix metal-loprotease-2 cleavage of laminin-5. Science. 277:225–228. 1997. View Article : Google Scholar : PubMed/NCBI
29.	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI
30.	Noë V, Fingleton B, Jacobs K, et al: Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci. 114:111–118. 2001.PubMed/NCBI
31.	Mañes S, Llorente M, Lacalle RA, et al: The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem. 274:6935–6945. 1999.PubMed/NCBI
32.	Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 103:1237–1241. 1999. View Article : Google Scholar : PubMed/NCBI